Market Overview:
The global human immunoglobulin market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of infectious diseases, rising demand for human immunoglobulin products for prophylaxis and treatment of various infections, and growing awareness about the benefits of human immunoglobulin products. The global human immunoglobulin market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into intramuscular injection and intravenous injection. Intravenous injection held a larger share in 2017 owing to its higher efficacy as compared to intramuscular injection. On the basis of application, the market is segmented into disease prevention, treatment, diagnosis, and other applications such as passive immunity therapy and research purposes.
Product Definition:
Human Immunoglobulin is a serum protein that confers immunity to infections. It is composed of immunoglobulins, which are proteins that specifically bind to antigens on the surface of bacteria, viruses, and other foreign objects. The antibodies in human immunoglobulin can recognize and neutralize a wide variety of pathogens.
Intramuscular Injection:
Intramuscular injection is a procedure wherein the drug or vaccine is injected into muscle. Intramuscular injections are usually used in humans and animals to deliver vaccines, drugs, and insulin.
Intravenous Injection:
Intravenous injection is a medical procedure wherein the drugs or vaccines are administered into the vein of the patient. The IV medication is preferred by doctors and patients owing to several advantages such as it allows for higher doses, reduces pain, enables rapid drug delivery, and improves efficacy.
The global intravenous injection market was valued at USD 13.5 billion in 2013.
Application Insights:
The disease prevention segment dominated the global human immunoglobulin market in 2017. This can be attributed to the rising incidence of diseases, such as diabetes and autoimmune disorders. For instance, according to a study published in NCBI in 2018, it is estimated that around 60 million people across the globe have diabetes or are at risk of developing diabetes. Furthermore, another study states that by 2040, prevalence of type 1 and type 2 will increase by approximately 30% per year globally. These factors indicate a significant demand for HIGs for disease prevention during the forecast period.
However, treatment accounted for a major share owing to an increasing number of patients suffering from chronic conditions who require regular injections or infusions over a longer period of time (months & years).
Regional Analysis:
North America dominated the global human immunoglobulin market in 2017. The presence of a large number of manufacturers and suppliers coupled with high healthcare expenditure levels is expected to drive the regional market over the forecast period. In addition, increasing incidence of diseases such as multiple sclerosis (MS), lupus, rheumatoid arthritis (RA) & Crohn’s disease among others are fueling product demand in North America.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising prevalence of autoimmune disorders coupled with growing awareness about preventive measures taken by individuals against these diseases. Moreover, increasing investments by major players for manufacturing and distribution expansion are expected to boost industry growth over next eight years.
Growth Factors:
- Increasing incidence of autoimmune diseases: The global prevalence of autoimmune diseases is increasing at an alarming rate. This is primarily attributed to the changing lifestyles and environmental factors. Immunoglobulin therapy is considered as one of the most effective treatment options for these conditions and hence, is likely to witness significant demand in the coming years.
- Growing awareness about immunoglobulins: There has been a growing awareness among healthcare professionals and patients about the benefits of immunoglobulin therapy. This is likely to boost demand for human immunoglobulin products in the coming years.
- Rising number of cancer patients: The incidence of cancer is on the rise globally, especially in developing countries. Immunotherapy has emerged as an important treatment modality for cancer patients and human immunoglobulins are widely used in this context. Thus, there exists a huge potential for growth in this market segment over the forecast period 2017-2025 .
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Immunoglobulin Market Research Report
By Type
Intramuscular Injection, Intravenous Injection
By Application
Disease Prevention, Treatment, Diagnosis, Other
By Companies
Shire, CSL, Grifols, Octapharma, Biotest, China National Pharmaceutical Group Corporation, CTBB, Hualan Bio, RASS, Shanxi Kangbao Biological Product, Shuanglin Bio Pharma, Sichuan Yuanda Shuyang Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Human Immunoglobulin Market Report Segments:
The global Human Immunoglobulin market is segmented on the basis of:
Types
Intramuscular Injection, Intravenous Injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Disease Prevention, Treatment, Diagnosis, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Shire
- CSL
- Grifols
- Octapharma
- Biotest
- China National Pharmaceutical Group Corporation
- CTBB
- Hualan Bio
- RASS
- Shanxi Kangbao Biological Product
- Shuanglin Bio Pharma
- Sichuan Yuanda Shuyang Pharmaceutical
Highlights of The Human Immunoglobulin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Intramuscular Injection
- Intravenous Injection
- By Application:
- Disease Prevention
- Treatment
- Diagnosis
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Immunoglobulin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Human immunoglobulin is a protein that helps the body fight against infection. It is made of two types of proteins, called IgG and IgA.
Some of the key players operating in the human immunoglobulin market are Shire, CSL, Grifols, Octapharma, Biotest, China National Pharmaceutical Group Corporation, CTBB, Hualan Bio, RASS, Shanxi Kangbao Biological Product, Shuanglin Bio Pharma, Sichuan Yuanda Shuyang Pharmaceutical.
The human immunoglobulin market is expected to grow at a compound annual growth rate of 6.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Human Immunoglobulin Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Human Immunoglobulin Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Human Immunoglobulin Market - Supply Chain
4.5. Global Human Immunoglobulin Market Forecast
4.5.1. Human Immunoglobulin Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Human Immunoglobulin Market Size (000 Units) and Y-o-Y Growth
4.5.3. Human Immunoglobulin Market Absolute $ Opportunity
5. Global Human Immunoglobulin Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Human Immunoglobulin Market Size and Volume Forecast by Type
5.3.1. Intramuscular Injection
5.3.2. Intravenous Injection
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Human Immunoglobulin Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Human Immunoglobulin Market Size and Volume Forecast by Application
6.3.1. Disease Prevention
6.3.2. Treatment
6.3.3. Diagnosis
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Human Immunoglobulin Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Human Immunoglobulin Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Human Immunoglobulin Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Human Immunoglobulin Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Human Immunoglobulin Demand Share Forecast, 2019-2026
9. North America Human Immunoglobulin Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Human Immunoglobulin Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Human Immunoglobulin Market Size and Volume Forecast by Application
9.4.1. Disease Prevention
9.4.2. Treatment
9.4.3. Diagnosis
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Human Immunoglobulin Market Size and Volume Forecast by Type
9.7.1. Intramuscular Injection
9.7.2. Intravenous Injection
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Human Immunoglobulin Demand Share Forecast, 2019-2026
10. Latin America Human Immunoglobulin Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Human Immunoglobulin Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Human Immunoglobulin Market Size and Volume Forecast by Application
10.4.1. Disease Prevention
10.4.2. Treatment
10.4.3. Diagnosis
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Human Immunoglobulin Market Size and Volume Forecast by Type
10.7.1. Intramuscular Injection
10.7.2. Intravenous Injection
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Human Immunoglobulin Demand Share Forecast, 2019-2026
11. Europe Human Immunoglobulin Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Human Immunoglobulin Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Human Immunoglobulin Market Size and Volume Forecast by Application
11.4.1. Disease Prevention
11.4.2. Treatment
11.4.3. Diagnosis
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Human Immunoglobulin Market Size and Volume Forecast by Type
11.7.1. Intramuscular Injection
11.7.2. Intravenous Injection
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Typ
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Human Immunoglobulin Demand Share, 2019-2026
12. Asia Pacific Human Immunoglobulin Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Human Immunoglobulin Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Human Immunoglobulin Market Size and Volume Forecast by Application
12.4.1. Disease Prevention
12.4.2. Treatment
12.4.3. Diagnosis
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Human Immunoglobulin Market Size and Volume Forecast by Type
12.7.1. Intramuscular Injection
12.7.2. Intravenous Injection
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Human Immunoglobulin Demand Share, 2019-2026
13. Middle East & Africa Human Immunoglobulin Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Human Immunoglobulin Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Human Immunoglobulin Market Size and Volume Forecast by Application
13.4.1. Disease Prevention
13.4.2. Treatment
13.4.3. Diagnosis
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Human Immunoglobulin Market Size and Volume Forecast by Type
13.7.1. Intramuscular Injection
13.7.2. Intravenous Injection
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Human Immunoglobulin Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Human Immunoglobulin Market: Market Share Analysis
14.2. Human Immunoglobulin Distributors and Customers
14.3. Human Immunoglobulin Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Shire
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. CSL
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Grifols
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Octapharma
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Biotest
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. China National Pharmaceutical Group Corporation
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. CTBB
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Hualan Bio
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. RASS
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Shanxi Kangbao Biological Product
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Shuanglin Bio Pharma
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Sichuan Yuanda Shuyang Pharmaceutical
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
